TR201901991T4 - Prostat spesifik kök hücre antijenine karşı antikor ve bunun kullanımı. - Google Patents

Prostat spesifik kök hücre antijenine karşı antikor ve bunun kullanımı. Download PDF

Info

Publication number
TR201901991T4
TR201901991T4 TR2019/01991T TR201901991T TR201901991T4 TR 201901991 T4 TR201901991 T4 TR 201901991T4 TR 2019/01991 T TR2019/01991 T TR 2019/01991T TR 201901991 T TR201901991 T TR 201901991T TR 201901991 T4 TR201901991 T4 TR 201901991T4
Authority
TR
Turkey
Prior art keywords
seq
stem cell
cell antigen
prostate specific
cdr
Prior art date
Application number
TR2019/01991T
Other languages
English (en)
Inventor
Bachmann Michael
Original Assignee
Gemoab Monoclonals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemoab Monoclonals Gmbh filed Critical Gemoab Monoclonals Gmbh
Publication of TR201901991T4 publication Critical patent/TR201901991T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Buluş, bir rekombinant prostat spesifik kök hücre antijeni (PSCA) bağlayan antikordur. Buluşa ait antikor, burada belirtilen amino asit sekanslarıyla tamamlayıcılık belirleyici bölgeler (CDR) kapsamaktadır: - hafif zincirin değişken bölgesi için CDR: CDR1 SEKANS KİMLİK No. 1, CDR2 SEKANS KİMLİK No. 2, CDR3 SEKANS KİMLİK No. 3 ve - ağır zincirin değişken bölgesi için CDR: CDR1 SEKANS KİMLİK No. 4, CDR2 SEKANS KİMLİK No. 5, CDR3 SEKANS KİMLİK No. 6. Ayrıca buluş, buluşa ait antikorun ilaç olarak, özellikle tümör hastalıklarının tedavisinde veya tanıda kullanılmasını kapsamaktadır. Antikorlar, tıp, farmasi ve biyomedikal araştırma alanlarında kullanıma uygun olmaktadır.
TR2019/01991T 2011-06-30 2012-06-29 Prostat spesifik kök hücre antijenine karşı antikor ve bunun kullanımı. TR201901991T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Publications (1)

Publication Number Publication Date
TR201901991T4 true TR201901991T4 (tr) 2019-03-21

Family

ID=46384405

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01991T TR201901991T4 (tr) 2011-06-30 2012-06-29 Prostat spesifik kök hücre antijenine karşı antikor ve bunun kullanımı.

Country Status (17)

Country Link
US (1) US9200078B2 (tr)
EP (2) EP3505536B1 (tr)
JP (4) JP2014528696A (tr)
AU (1) AU2012277784B2 (tr)
CY (1) CY1121249T1 (tr)
DE (1) DE102011118022B4 (tr)
DK (1) DK2726507T3 (tr)
ES (1) ES2711978T3 (tr)
HR (1) HRP20190289T1 (tr)
HU (1) HUE042008T2 (tr)
LT (1) LT2726507T (tr)
PL (1) PL2726507T3 (tr)
PT (1) PT2726507T (tr)
RS (1) RS58448B1 (tr)
SI (1) SI2726507T1 (tr)
TR (1) TR201901991T4 (tr)
WO (1) WO2013001065A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343085B1 (en) * 1997-03-10 2014-12-10 The Regents of The University of California Antibody against prostate stem cell antigen (PSCA)
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
IL149116A0 (en) * 1999-10-29 2002-11-10 Genentech Inc Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
AU2004283850C1 (en) * 2003-10-16 2011-11-03 Amgen Research (Munich) Gmbh Multispecific deimmunized CD3-binders
EP1753871B1 (en) * 2004-05-28 2015-07-15 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
EP2197491A4 (en) * 2007-09-04 2011-01-12 Univ California HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Also Published As

Publication number Publication date
AU2012277784B2 (en) 2015-08-20
LT2726507T (lt) 2019-04-10
PL2726507T3 (pl) 2019-06-28
JP7341185B2 (ja) 2023-09-08
JP2021121201A (ja) 2021-08-26
DK2726507T3 (en) 2019-03-11
WO2013001065A1 (de) 2013-01-03
EP2726507A1 (de) 2014-05-07
SI2726507T1 (sl) 2019-05-31
AU2012277784A1 (en) 2014-02-06
HRP20190289T1 (hr) 2019-05-03
EP3505536B1 (de) 2024-08-07
HUE042008T2 (hu) 2019-06-28
PT2726507T (pt) 2019-02-26
JP6886491B2 (ja) 2021-06-16
DE102011118022A1 (de) 2013-01-03
EP3505536C0 (de) 2024-08-07
EP2726507B1 (de) 2018-11-21
JP2019193652A (ja) 2019-11-07
CY1121249T1 (el) 2020-05-29
US20140134155A1 (en) 2014-05-15
JP2014528696A (ja) 2014-10-30
EP3505536A1 (de) 2019-07-03
US9200078B2 (en) 2015-12-01
RS58448B1 (sr) 2019-04-30
JP2017104113A (ja) 2017-06-15
ES2711978T3 (es) 2019-05-08
DE102011118022B4 (de) 2018-01-18
JP6549622B2 (ja) 2019-07-24

Similar Documents

Publication Publication Date Title
NZ610734A (en) Human antibodies to the glucagon receptor
TR201901991T4 (tr) Prostat spesifik kök hücre antijenine karşı antikor ve bunun kullanımı.
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
RU2014138041A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
MX348577B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2014138040A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
MX2021007006A (es) Anticuerpo anti-calicreina-2 humanizado.
JP2014511179A5 (tr)
NZ599405A (en) Targeted binding agents against b7-h1
RU2013140625A (ru) Антитела против ангиопоэтина-2 человека
NZ575245A (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
JP2017508475A5 (tr)
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
BR112014002613A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método
EP2471817A3 (en) Humanized antibody molecules specific for IL-31
SI2579894T1 (en) CGRP PROTITELESA
NZ630433A (en) Antibodies and uses thereof to detect folate receptor 1
NZ624752A (en) Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease